The UMKC School of Medicine has received a nearly $400,000 grant from the National Institutes of Health to continue and build upon a successful two-year training program in clinically-oriented cardiovascular disease outcomes research through the Department of Biomedical and Health Informatics and UMKC’s new Healthcare Institute for Innovations in Quality (HI-IQ).
The funding covers the first of five years of support through the National Heart, Lung and Blood Institute, bringing the total grant funding to just less than $2 million.
Immense research investments have improved the care of patients afflicted with cardiovascular disease, the leading cause of death and disability in the United States. But continued evaluation of patient-centered outcomes, including patient symptoms, function and quality of life, and how to apply that knowledge in clinical settings is needed, said John Spertus, M.D., professor, clinical director and endowed chair in metabolic and vascular disease research.
“Collectively, our committed team will provide formal training, mentorship and research experiences for trainees to make significant contributions to the scientific literature, embark on successful academic careers, and improve the value and patient-centeredness of medical care,” Spertus said.
Hands-on research is one of the key components of the program that provides a basic foundation in clinical research, including a master’s degree in bioinformatics with a clinical research emphasis, and specialized skills for outcomes research, coupled with academic survival skills.
Hallmarks of the research experiences include multi-disciplinary group and individualized mentorship to meet each trainee’s needs, as well as access to numerous existing data. Clinical populations for primary data collection and implementation, training in entrepreneurship, and highly experienced statistical support are provided to support trainees’ success.
Program enhancements are also planned that include a more robust collaboration with the University of Missouri system, increased engagement in clinical trial design and a growing focus on implementation science with access to HI-IQ’s multistakeholder collaboration of 19 regional hospitals.